Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Integral Diagnostics Ltd. ( (AU:IDX) ) is now available.
Integral Diagnostics has reported a sharp turnaround in its half-year results to 31 December 2025, with revenue from ordinary activities jumping 55.6% to $393.5 million and EBITDA rising 91.4% to $67.1 million. EBIT climbed 161.8% to $30.2 million and profit after tax attributable to shareholders reached $9.0 million, compared with a loss a year earlier, reflecting the full period contribution from the Capitol Health acquisition.
Despite the improved profitability, net tangible assets per share remained negative at 109.67 cents, highlighting a capital structure still weighed down by intangibles. The board nonetheless signalled confidence in cash generation by lifting the fully franked interim dividend to 3.3 cents per share, up from 2.5 cents, and confirmed the continuation of its dividend reinvestment plan for the first half of FY26.
The most recent analyst rating on (AU:IDX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited is an Australian healthcare services provider specialising in diagnostic imaging. The company operates radiology practices that deliver medical imaging services to patients and referrers across its markets, with a focus on leveraging scale and acquisitions to grow revenue and earnings.
Average Trading Volume: 583,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$905.7M
For a thorough assessment of IDX stock, go to TipRanks’ Stock Analysis page.